Salipro Biotech AB announced that it has entered into a research collaboration and license agreement with Sanofi on the discovery of therapeutic biologics against a challenging drug target. The collaboration brings together Salipro Biotech's unique expertise in developing stable antigens of GPCRs, ion channels and transporters via its proprietary Salipro® platform with Sanofi's discovery programs to identify biologics with the desired therapeutic properties against a selected target.